A process for the purification of Bosentan sodium and a novel crystalline form of substantially pure Bosentan sodium to disclosed in this invention.

The present invention provides methods of treating Alport syndrome in a subject by the administration of an agent that can blocks the activation of RAC1/CDC42 members of the rho family of small GTPases. Such agents include, but are not limited to, the endothelin receptor antagonist bosentan. Such administration prevents invasion of the glomerular capillary tufts by mesangial lamellipodial/filopodial processes, blocks mesangial process invasion abrogates the deposition of laminin 211 in the GBM, ...

The present invention relates to a process for the preparation of Bosentan (Formula 1) or pharmaceutically acceptable salts or hydrates thereof which results the product substantially free of impurities like ethylene glycol bis-sulfonamide dimer and 6-hydroxy sulfonamide. The process according to present invention is also producing Bosentan sodium and Bosentan ammonium which gives Bosentan or pharmaceutically acceptable salts or hydrates thereof in improved yield and quality as compared to prior...

600010 Disclosed is Crystalline form 6 of bosentan (4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide), characterized by an X-ray diffraction pattern comprising peaks at values 3.87, 7.51, 8.84, 11.14, 18.74 and 23.30 -0.2 plus or minus 0.2 degrees theta. The crystalline form of bosentan is useful for treating or preventing an endothelien receptor mediated disorder such as cardiovascular disorders. Specific cardiovascular disorders trea...

The present invention provides: a bosentan controlled release oral preparation comprising bosentan as an active ingredient, a pharmaceutically acceptable salt thereof, or a solvate thereof, and an extended release material

The present invention relates to an improved process for preparing Bosentan of formula (I).

A novel ammonium salt of Bosentan of formula (VIII)

Process for the purification of N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulphonamide (bosentan), intermediates useful in said process, and their preparation.